Scientific Sessions 2024  /  Featured Science: Novel Approaches to Managing Lipid Risk  /  Discussant: LIBerate-OLE, LIBerate-HeFH_OLE
Logo

American Heart Association

  169
  0

Final ID:

Discussant: LIBerate-OLE, LIBerate-HeFH_OLE

  • O'donoghue, Michelle  ( BRIGHAM WOMENS HOSP , BOSTON , Massachusetts , United States )
    • Author Disclosures:
    Michelle O'Donoghue: DO have relevant financial relationships ; Consultant:Janssen:Active (exists now) ; Consultant:NovoNordisk:Active (exists now) ; Consultant:Verve:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Researcher:AstraZeneca:Active (exists now) ; Researcher:Marea:Active (exists now) ; Researcher:Novartis:Active (exists now) ; Researcher:Amgen:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Novel Approaches to Managing Lipid Risk

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Featured Science

More abstracts on this topic:
PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP)

Watts Gerald, Hellawell Jennifer, Leeper Nick, Gaudet Daniel, Hegele Robert, Rosenson Robert, Goldberg Ira, Gallo Antonio, Mertens Ann, Baass Alexis, Fu Ran, Muhsin Maan

Discussant: YELLOW III

Mora Samia, Kramer Christopher

More abstracts from these authors:
The New Guideline in a Global Context: Writing Committee Reply

O'donoghue Michelle, Sandner Sigrid, Tamis-holland Jacqueline

Lp(a) and ASCVD: What does the causal link mean for risk reduction in practice?

O'donoghue Michelle

You have to be authorized to contact abstract author. Please, Login
Not Available